Clinical Trial Update: Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery [Phase 1, Phase 2]

View source ↗

Summary

This terminated Phase 1/2 trial assessed the safety and tolerability of CX-4945 (silmitasertib) in pediatric patients with recurrent medulloblastoma, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma

Drugs mentioned

• CX-4945 (silmitasertib)

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Medulloblastoma, Childhood, Medulloblastoma Recurrent | Phase 1, Phase 2 | Status: TERMINATED